Insights on cisplatin-resistant cell populations through mass cytometry analysis of ovarian cancer

Identification: Casado, Julia


Insights on cisplatin-resistant cell populations through mass cytometry analysis of ovarian cancer

Julia Casado1, Katja Kaipio2, Luca Pasquini3, Rainer Lehtonen1, Mauro Biffoni3, Olli Càrpen2, Sampsa Hautaniemi1

1Research Programs Unit, Faculty of Medicine, University of Helsinki; 2Department of Pathology, University of Turku; 3Istituto Superiore di Sanità, Department of Haematology

High-grade serous ovarian cancer (HGSOC) is an aggressive gynecological cancer and the most common subtype of ovarian cancer. Despite primary debulking surgery and platinum-based treatments more than half of the patients die within five years after diagnosis [1]. High intra-tumoral heterogeneity, a common characteristic of HGSOC, is a hallmark of chemoresistance [2]. A detailed characterisation of the specific cancer clones that drive resistance to platinum therapies is therefore needed in order to predict the prognosis and describe cell population profiles for future patients.

Here, we utilized a comprehensive mass cytometry analysis with a panel of 27 antibodies to identify these cell populations as part of the HERCULES EU project. We studied samples taken at two time points, at the time of primary debulking surgery and at disease progression. Tumor profiles across time points were described using our novel computational framework which integrates state of the art methods in the field and interactive visualization tools.

Identifying the key features of each cell population provides an insight into the chemoresistance potential of a given tumor. These results will help clinicians predict prognosis and suggest personalized therapies targeting cisplatin resistant cell populations thus improving disease outcome.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 667403, as well as Academy of Finland grants 305087 and 284598.

[1]. Usha Nagavarapu. Therapies and Diagnostics for Ovarian Cancer. BCC Research, June 2013. HLC143A.

[2]. Schwarz et al. Spatial and Temporal Heterogeneity in High-Grade Serous Ovarian Cancer: A Phylogenetic Analysis. PLOS Med doi: 10.1371/journal.pmed.1001789


Credits: None available.